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TGF-b1 is a regulatory cytokine with a pleiotro-
pic role in immune responses. TGF-b1 is widely
expressed in leukocytes and stromal cells.
However, the functions of TGF-b1 expressed
by specific lineages of cells remain unknown
in vivo. Here, we show that mice with a T cell-
specific deletion of the Tgfb1 gene developed
lethal immunopathology in multiple organs, and
this development was associated with en-
hanced T cell proliferation, activation, and
CD4+ T cell differentiation into T helper 1 (Th1)
and Th2 cells. TGF-b1 produced by Foxp3-
expressing regulatory T cells was required to in-
hibit Th1-cell differentiation and inflammatory-
bowel disease in a transfer model. In addition,
T cell-produced TGF-b1 promoted Th17-cell
differentiation and was indispensable for the in-
duction of experimental autoimmune encepha-
lomyelitis. These findings reveal essential roles
for T cell-produced TGF-b1 in controlling differ-
entiation of T helper cells and controlling inflam-
matory diseases.
INTRODUCTION
Transforming growth factor-b1 (TGF-b1) is a regulatory
cytokine with an essential role in immune responses (Li
et al., 2006b). TGF-b1 is produced by virtually all cell types
and mediates pleiotropic functions on leukocytes. The
utmost importance of TGF-b1 in the immune system is un-
derscored by the finding that TGF-b1-deficient mice de-
veloped a multifocal inflammatory disease that led to their
early demise at approximately 3–4 weeks of age (Kulkarni
et al., 1993; Shull et al., 1992).
Studies with cell-type-specific targeting strategies have
revealed that T cells are a key target of TGF-b1 in vivo. Ex-
pression of a dominant-negative form of TGF-b receptor II
(TGF-bRII) from theCd4 promoter (CD4-DNRII) in mice at-
tenuated TGF-b signaling in T cells (Gorelik and Flavell,
2000). These mice developed an inflammatory phenotypeassociated with T cell activation and differentiation
(Gorelik and Flavell, 2000). In another report, expression
of DNRII from the Cd2 promoter leads to a CD8+ T cell
lymphoproliferative disorder (Lucas et al., 2000). These
transgenic mice are likely to retain some TGF-b signaling
in T cells because T cell-specific deletion of TGF-bRII
results in an autoimmune phenotype as severe as that of
TGF-b1-deficient mice (Li et al., 2006a; Marie et al.,
2006). These recent studies have also revealed pleiotropic
functions for TGF-b signaling in T cell development and
tolerance. Thus, TGF-b promotes CD8+ T cell and natu-
ral-killer T cell development and inhibits the proliferation
of Foxp3-expressing thymic regulatory T (Treg) cells. In
peripheral tissues, TGF-b inhibits T cell proliferation, T
cell activation, and effector T-cell differentiation andmain-
tains Treg cells (Li et al., 2006a; Marie et al., 2006). This
dual effect of TGF-b on effector T cells and Treg cells is
likely to contribute to its regulation of peripheral T cell
tolerance.
Recent studies have also uncovered an important func-
tion for TGF-b in the differentiation of IL-17-producing
helper T cells called Th17 cells (Bettelli et al., 2006; Man-
gan et al., 2006; Veldhoen et al., 2006a). In vitro antigen
stimulation of T cells in the presence of TGF-b induces
Foxp3 expression and Treg-cell differentiation (Chen
et al., 2003; Fantini et al., 2004). The addition of IL-6 repro-
grams T cells to differentiate into Th17 cells (Bettelli et al.,
2006; Veldhoen et al., 2006a). Although the precise in vivo
functions of Th17 cells remain to be fully explored, Th17
cells drive autoimmune diseases including experimental
autoimmune encephalomyelitis (EAE) and collagen-
induced arthritis (Cua et al., 2003; Langrish et al., 2005;
Murphy et al., 2003). In support of an important role for
TGF-b in Th17-cell differentiation, CD4-DNRII mice are
resistant to the induction of EAE (Veldhoen et al., 2006b).
TGF-b1 is produced by multiple lineages of leukocytes
and stromal cells (Li et al., 2006b). However, the essential
sources of TGF-b1 and the cellular mechanisms whereby
T cells are regulated are unknown. Endocrine expression
of active TGF-b1 in TGF-b1-deficient mice failed to
ameliorate the lethal phenotype (Longenecker et al.,
2002). Local but not systemic administration of neutraliz-
ing TGF-b1 antibody inhibits Th17-cell differentiation and
the induction of EAE (Veldhoen et al., 2006b). TheseImmunity 26, 579–591, May 2007 ª2007 Elsevier Inc. 579
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In Vivo Function of T Cell-Produced TGF-b1studies suggest that TGF-b regulation of T cell tolerance
and Th17-cell differentiation might be mediated by auto-
crine, paracrine, or both sources of TGF-b1.
Early studies showed that activated T cells produce
TGF-b1 (Kehrl et al., 1986). TGF-b1 produced by Treg cells
has also been suggested to be amechanism for Treg-cell-
mediated immune suppression, although conflicting re-
sults have been reported. A fraction of Treg cells express
TGF-b1 on their surface, and this has been suggested to
mediate their suppressor function in vitro (Green et al.,
2003; Nakamura et al., 2001). However, TGF-b1-deficient
Treg cells inhibit proliferation of responder T cells in vitro
(Piccirillo et al., 2002), indicating that TGF-b1 synthesis
by Treg cells is not required for cell-contact-dependent
suppression in vitro. The protective activity of Treg cells
against inflammatory-bowel disease induced by transfer
of CD4+CD45Rbhi T cells into severe combined immune
deficiency (SCID) mice is reversed by the treatment with
TGF-b antibody (Powrie et al., 1996). However, in an auto-
immune gastritis model, Treg-cell-mediated protection is
not alleviated by the same treatment (Piccirillo et al.,
2002). Even in the same colitis model, TGF-b1-deficient
Treg cells were shown to be protective or nonfunctional
depending on experimental systems (Fahlen et al., 2005;
Kullberg et al., 2005; Nakamura et al., 2004). One compli-
cation of these studies is that TGF-b1-deficient mice de-
velop an early inflammatory disease, and activated T cells
may contaminate the isolated CD4+CD25+ Treg-cell pop-
ulation. Therefore, the function of Treg-cell-produced
TGF-b1 remains to be established.
To investigate the cell-type-specific function of TGF-b1,
we generated mice in which the Tgfb1 gene can be inac-
tivated by using the Cre-loxP system (Rajewsky et al.,
1996). In this report, we show that T cell-produced TGF-
b1 inhibited thymic Treg-cell expansion and peripheral
T cell proliferation, activation, and differentiation; in the
absence of this inhibition, mice developed a lethal inflam-
matory disorder. In addition, Treg-cell-produced TGF-b1
was required for the inhibition of Th1-cell differentiation
and colitis. To our surprise, T cell-produced TGF-b1 was
essential for the differentiation of Th17 cells and the induc-
tion of EAE.
RESULTS
Generation of Mice with T Cell-Specific Deletion
of Tgfb1 Gene
To investigate the cell-type-specific function of TGF-b1
in vivo, we generated mice with a mutated Tgfb1 allele
by the insertion of two loxP sites flanking its promoter re-
gion and the first exon (Figure 1A). Tgfb1 exon 1 encodes
the leader peptide that directs secretion of TGF-b1 pro-
tein. loxP sites were introduced into the Tgfb1 locus by ho-
mologous recombination in mouse embryonic stem (ES)
cells (Figure 1B, left). The neomycin resistance gene (Neo)
was removed from homologous recombinants by tran-
sient transfection with a Cre expression plasmid (Fig-
ure 1B, right). Clones carrying the Tgfb1 locus with exon
1 flanked by loxP sites (floxed allele, f) were used for gen-580 Immunity 26, 579–591, May 2007 ª2007 Elsevier Inc.erating chimeric mice that produced heterozygous mice
after germline transmission. At the time that we generated
thesemice, there was no known gene in close proximity to
Tgfb1 promoter region. However, a hypothetical gene
(LOC232987) was later predicted in this region, the exon
4 of which resided 340 base pair upstream of the tran-
scriptional start site of Tgfb1 gene (Figure 1A). Therefore,
in addition to Tgfb1 exon 1, LOC232987 exon 4 was also
encompassed by the loxP sites (Figure 1A).
Mice with two floxed alleles (f/f) developed normally,
and did not show any sign of disease. To study the func-
tion of T cell-produced TGF-b1, we initially crossed f/f
mice with CD4-Cre transgenic mice (Lee et al., 2001), in
which Cre is specifically expressed in T cells. Recombina-
tion of the Tgfb1 locus (deleted allele, d) was detected in
the thymus of the CD4-Cre+f/f (4cre-f/f) mice (Figure 1C),
which resulted in more than 90% deletion of the loxP-
flanked region in peripheral CD4+ and CD8+ T cells but
not in B cells, dendritic cells, or macrophages (Figure 1C).
Activated 4cre-f/f CD4+ T cells did not produce detectable
amounts of TGF-b1 protein compared to control f/f CD4+
T cells (Figure 1D), demonstrating efficient ablation of
TGF-b1 expression in these cells. The hypothetical protein
LOC232987 was expressed in T cells (Figure 1F, left lane).
As predicted, its exon 4 was also deleted in 4cre-f/f CD4+
T cells (Figure 1F, middle lane).
To eliminate the influence of lack of LOC232987 exon 4
in T cells, we used a strain of mice with an insertion of the
coding region of green-fluoresent protein (GFP) to the first
exon of the Tgfb1 gene (Figure 1E). Because the stop co-
don of the GFP open-reading frame precedes the start
codon of the Tgfb1 gene, the GFP knockin allele was pre-
dicted to generate a Tgfb1 null allele (n). This was con-
firmed by the generation of mice homozygous for the
GFP knockin allele. These mice developed an early lethal
multifocal inflammatory disorder (Figure S1A in the Sup-
plemental Data available online), which was associated
with T cell activation (Figure S1B). These phenotypes
were similar to those of the originally reported TGF-b1-de-
ficient mice (Kulkarni et al., 1993; Shull et al., 1992). We
crossed n/+ mice with 4cre-f/+ mice to generate 4cre-f/n
mice. Because the LOC232987 locus is intact in the
Tgfb1 null allele, 4cre-f/n CD4+ T cells expressed
LOC232987 (Figure 1F, right lane). Importantly, CD4+ T
cells isolated from 4cre-f/n mice (both Foxp3-positive
Treg cells and Foxp3-negative non-Treg cells) did not pro-
duce detectable amounts of TGF-b1 protein compared to
that of control +/n T cells (Figure 1G). These observations
reveal that Tgfb1 gene was specifically abrogated in T
cells from 4cre-f/n mice.
Development of Immunopathology in the Absence
of T Cell-Produced TGF-b1
4cre-f/n mice appeared to be healthy until 4 months of
age, when they started to display signs of wasting and di-
arrhea that led to their early lethality starting at 6months of
age. Upon histological examination, we observed heavy
mononuclear cell infiltration in mucosal lamina propria
and the subglandular area of the colons in all 4cre-f/n
Immunity
In Vivo Function of T Cell-Produced TGF-b1Figure 1. Generation of Mice with T Cell-Specific Deletion of the Tgfb1 Gene
(A) Schematic presentation of the wild-type allele (WT, +), the mutated alleles after homologous recombination, and Cre-mediated deletion (Floxed
allele, f; deleted allele, d). The locations of the probes for Southern blotting and restriction-enzyme sites (E, EcoRI; S, SpeI) are indicated. Filled boxes
represent exons. loxP sites are depicted as arrowheads.
(B) Southern-blot analysis of an embryonic stem cell clone (#79) positive for recombination (left) and a subclone (#79.15) positive for the selective
removal of the neo gene (right).
(C) PCR analysis of purified DNA from thymocytes, CD4+ T cells, CD8+ T cells, B cells (B), dendritic cells (DC), and macrophages (Mph) of a 4cre-f/f
mouse. The floxed allele (f) and the deleted allele (d) are indicated.
(D) f/f and 4cre-f/f CD4+ T cells were stimulated with CD3 and CD28 antibodies in the presence of IL-2 for 3 days and were restimulated with CD3
antibody for 24 hr. TGF-b1 amounts in culture supernatant were determined by ELISA. The asterisk indicates what is undetectable by assays.
(E) Schematic presentation of a Tgfb1 null allele (n) with the knockin of GFP open-reading frame to the first exon of Tgfb1 gene. The stop codon of the
GFP gene is depicted.
(F) Wild-type (WT), 4cre-f/f, and 4cre-f/n CD4+ T cells were purified. Expression of LOC232987 and HPRT in these cells was analyzed by RT-PCR.
(G) +/n and 4cre-f/n CD4+Foxp3 and CD4+Foxp3+ T cells were stimulated with CD3 and CD28 antibodies in the presence of IL-2 for 24 hr. TGF-b1
amounts in culture supernatant were determined by ELISA. Asterisks indicate what are undetectable by assays.Immunity 26, 579–591, May 2007 ª2007 Elsevier Inc. 581
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In Vivo Function of T Cell-Produced TGF-b1Figure 2. Development of Immunopa-
thology in the Absence of T Cell-Pro-
duced TGF-b1
(A) Hematoxylin and eosin staining of colon,
liver, and lung sections (2003) of 4cre-f/n and
+/n mice at 6 months old. These are represen-
tative results of eight mice per group analyzed.
(B) Nuclear antibody (NA) and dsDNA antibody
(DA) titers in the sera of 4cre-f/n mice com-
pared to those of control +/n, 4cre-f/+, f/n, or
f/f (WT-Het) mice aged 4–7 months (n = 8).
The p values of antibody titers between the
two groups of mice are shown.
(C) Frozen kidney sections of 4cre-f/n or 4cre-
f/+ mice were stained with Alexa-Fluor-488-
labeled goat anti-mouse IgG antibody. Five
mice per group were analyzed. A representa-
tive picture is shown (2003).mice aged 4–12 months (Figure 2A, left panel). Severe
colitis was associated with the disruption of crypt archi-
tecture, formation of crypt abscesses, and compensatory
epithelium hyperplasia (Figure 2A and data not shown). In
the livers of these mice, clusters of mononuclear cells
were detected in parenchema (Figure 2A, middle panel).
Mononuclear cell infiltration was also evident in the lungs
of these mice (Figure 2A, right panel). A similar inflamma-
tory disorder was observed in 4cre-f/f mice (data not
shown). However, none of these changes was detected
in control +/n, 4cre-f/+, f/n, or f/f mice (Figure 2A and
data not shown).
TGF-b1 complete knockoutmice lose self tolerance and
produce autoreactive antibodies (Dang et al., 1995; Yas-
wen et al., 1996). To investigate whether T cell-produced
TGF-b1 is required for maintaining self tolerance, the
amounts of autoantibodies in the sera of these mice
were measured. Importantly, increased titers of both nu-
clear and dsDNA antibodies were detected in the sera of
4cre-f/n mice (Figure 2B). Because the presence of auto-582 Immunity 26, 579–591, May 2007 ª2007 Elsevier Inc.immune antibodies frequently leads to formation of im-
mune complexes and their deposition in kidney glomeruli,
we tested whether this process occurred in 4cre-f/n mice.
Specific IgG deposits were detected in the kidney sec-
tions of 4cre-f/n mice but not those of 4cre-f/+ mice
(Figure 2C), suggesting pathogenic functions of the auto-
reactive antibodies. These observations demonstrate that
T cell-produced TGF-b1 is essential for the inhibition of
immunopathology in multiple organs.
TCell Development andHomeostasis in the Absence
of T Cell-Produced TGF-b1
The immunopathology developed in 4cre-f/n mice resem-
bled that of CD4-DNR mice, which had attenuated TGF-
b signaling in T cells (Gorelik and Flavell, 2000), suggesting
that T cell-produced TGF-b1 regulated T cell responses.
To investigate the T cell phenotypes, we first studied T
cell development in 4cre-f/n mice. Our recent study of
mice with T cell-specific deletion of the Tgfbr2 gene
showed that TGF-b positively regulates CD8+ T cell
Immunity
In Vivo Function of T Cell-Produced TGF-b1Figure 3. T Cell Development and Homeostasis in the Absence of T Cell-Produced TGF-b1
(A) The thymic CD4, CD8, and TCR-b profile of 4cre-f/n and +/n mice at 6 weeks old. These are representative profiles of six mice per group analyzed.
(B) The thymic Foxp3-RFP and TCR-b profile of 4cre-f/n and +/nmice at 6 weeks old. This is a representative picture of eight mice per group analyzed.
(C) Number of CD4+Foxp3, CD4+Foxp3+, or CD8+ T cells in the mesenteric lymph nodes of 4cre-f/n or littermate control +/n, 4cre-f/+, f/n, or f/f
(WT-Het) mice (n = 6) at 6–8 weeks old. The p values of cell numbers between the two groups of mice are indicated.
(D) BrdU staining of mesenteric-lymph-node CD4+Foxp3, CD4+Foxp3+, and CD8+ T cells isolated from +/n and 4cre-f/n mice at 8 weeks old. These
are representative results of three mice per group analyzed.Immunity 26, 579–591, May 2007 ª2007 Elsevier Inc. 583maturation (Li et al., 2006a). Analysis of young 4cre-f/n
mice aged 4–8 weeks revealed normal thymic cellularity
(data not shown). The subset distribution of 4cre-f/n
CD4+ and CD8+ T cells is not drastically different from
that of control T cells, although a slight decrease of
CD8+TCR-bhi T cells was observed (Figure 3A). Thymic se-
lection also results in the generation of Treg cells whose
development and function are specified by the transcrip-
tion factor Foxp3 (Fontenot and Rudensky, 2005; Sakagu-
chi, 2004). To investigate the function of T cell-produced
TGF-b1 in Treg-cell development, we crossed 4cre-f/n
mice with Foxp3-RFP mice that contain knockin allelesof red-fluorescent protein (RFP) in the Foxp3 locus (Wan
and Flavell, 2005). Deficiency of T cell-produced TGF-b1
led to a 2-fold increase of thymic Foxp3-positive Treg cells
(Figure 3B). We have reported a similar increase of thymic
Treg cells in mice with T cell-specific deletion of the Tgfbr2
gene (Li et al., 2006a). These observations demonstrate
that T cell-produced TGF-b1 plays a nonredundant role
in limiting the expansion of thymic Treg cells.
Studies of mice with T cell-specific inactivation of TGF-
b signaling, or of TGF-b1-deficient mice, showed that
TGF-b1 is required for the maintenance of peripheral
Treg cells (Li et al., 2006a; Marie et al., 2005; Marie
Immunity
In Vivo Function of T Cell-Produced TGF-b1et al., 2006).We have also found that despite the decrease
of peripheral Treg cells, TGF-bRII-deficient Treg cells un-
dergo high rates of proliferation (Li et al., 2006a). These
observations suggest that the TGF-b pathway has a dual
role in the inhibition of Treg-cell proliferation and in the
maintenance of Treg cells. For investigating the function
of T cell-produced TGF-b1 in these processes, peripheral
Treg cells were examined in 4cre-f/n mice. Deletion of
Tgfb1 gene in T cells did not result in a decrease of the fre-
quencies of Treg cells in the mesenteric lymph nodes, pe-
ripheral lymph nodes, and spleens of 4cre-f/n mice
(Figure S2A). Substantial numbers of Treg cells were
also detected among the lamina propria mononuclear
cells that infiltrated the colons of 4cre-f/n mice (Fig-
ure S2B). Interestingly, the expression of Foxp3 was lower
in colonic Treg cells than mesenteric-lymph-node Treg
cells (Figure S2B). Importantly, the number of Treg cells in-
creased 2-fold in the mesenteric lymph nodes of 4cre-f/n
mice compared to that of control mice (Figure 3C). To test
whether increased Treg cells were due to enhanced prolif-
eration, we pulse-labeled 4cre-f/n and +/n mice with BrdU
for 16 hr. A higher percentage of Treg cells from the mes-
enteric lymph nodes of 4cre-f/n mice incorporated BrdU
than that of control +/n mice (Figure 3D). Increased num-
ber and enhanced proliferation of CD4+Foxp3 T cells and
CD8+ T cells were also observed in the mesenteric lymph
nodes of 4cre-f/n mice compared to those of control mice
(Figures 3C and 3D), and such a finding was associated
with the development of severe colitis in these mice
(Figure 2A). These findings reveal that T cell-produced
TGF-b1 is required to inhibit T cell proliferation but is dis-
pensable for the maintenance of Treg cells in peripheral
lymphoid organs. By inference, TGF-b1 sources other
than T cells may be able to provide this function.
T Cell Activation and Differentiation in the Absence
of T Cell-Produced TGF-b1
In addition to themaintenance of Treg cells, we and others
have reported that TGF-b signaling is required for the inhi-
bition of T cell activation and differentiation (Li et al.,
2006a; Marie et al., 2006). To study the function of T
cell-produced TGF-b1 in T cell activation, we examined
the expression of T cell activation markers CD44 and
CD62L in CD4+ and CD8+ T cells isolated from the mesen-
teric lymph nodes of 4cre-f/n mice. Compared to control
+/n T cells, a higher percentage of 4cre-f/n T cells ex-
hibited an activated CD44hiCD62Llo phenotype (Fig-
ure 4A). 4cre-f/n CD4+ and CD8+ T cells also expressed
greater amounts of surface CD122 (Figure 4B), the shared
receptor for IL-2 and IL-15. We and others have recently
shown that CD122 expression is controlled by transcrip-
tion factors T-bet and eomesodermin that also regulates
effector Th1 and CTL functions (Intlekofer et al., 2005;
Li et al., 2006a). These observations suggested that
4cre-f/n CD4+ and CD8+ T cells may undergo effector
T cell differentiation.
To determine T cell differentiation, we activated mesen-
teric-lymph-node T cells with CD3 and CD28 antibodies
for 24 hr and examined the secretion of IFN-g, IL-4, and584 Immunity 26, 579–591, May 2007 ª2007 Elsevier Inc.IL-17, the signature cytokines of Th1, CTL, Th2, and
Th17 cells. 4cre-f/n T cells produced greater amounts of
IFN-g and IL-4 but lesser amounts of IL-17 compared to
control T cells (Figure 4C). In order to determine the pro-
portion of T cells capable of cytokine production, we stim-
ulated T cells frommesenteric lymph nodes with PMA and
inonomycin for 4 hr and performed intracellular cytokine
staining. Compared to T cells from the +/n mouse, which
had only a few CD4+ and CD8+ T cells capable of IFN-g
and IL-4 production, a higher percentage of CD4+ and
CD8+ T cells from the 4cre-f/n mouse produced these
cytokines (Figure 4D, left and middle panels). In contrast,
fewer 4cre-f/n CD4+ T cells produced IL-17 than +/n
CD4+ T cells (Figure 4D, right panel). In addition, we exam-
ined the differentiation of CD4+ T cells that infiltrated the
colons of 4cre-f/n mice. Similar to mesenteric-lymph-
node T cells, the frequency of colonic IFN-g-producing
CD4+ T cells was higher, whereas the frequency of IL-
17-producing CD4+ T cells was lower in 4cre-f/n CD4+ T
cells compared to control f/n CD4+ T cells (Figure S3).
These observations demonstrate that T cell-produced
TGF-b1 promotes Th17-cell differentiation but inhibits
Th1, Th2, and CTL differentiation in vivo; the lack of this
function leads to severe colitis in 4cre-f/n mice.
Inhibition of Colitis by CD4+Foxp3+ Treg-Cell- and
Naive T Cell-Produced TGF-b1
We are interested in the prevalent colitis phenotype that
developed in 4cre-f/n mice. Because both CD4+Foxp3+
Treg cells and CD4+Foxp3 T cells that were activated
in vitro produced TGF-b1 (Figure 1G), we wished to deter-
mine their function in vivo. To this end, we crossed 4cre-
f/n mice with Foxp3-RFP mice and isolated Treg cells on
the basis of the expression of RFP, which faithfully marks
Foxp3-expressing Treg cells (Wan and Flavell, 2005). We
first tested the function of TGF-b1-deficient Treg cells in
vitro. 4cre-f/n Treg cells inhibited naive T cell proliferation
as potently as control Treg cells (Figure S4). These obser-
vations are consistent with cell-contact-dependent but
cytokine-independent mechanisms of Treg-cell suppres-
sion of proliferation in vitro.
To determine the activity of 4cre-f/n Treg cells in vivo,
we used a transfer model of colitis. In this model, transfer
of naive CD4+ cells into lymphopenic hosts leads to the
development of colitis, which can be prevented by the co-
transfer of Treg cells (Powrie et al., 1994). Previous studies
showed that the protection can be abrogated by the treat-
ment with TGF-b antibody (Powrie et al., 1996), and Treg
cells fail to inhibit colitis induced by naive CD4-DNR
CD4+ T cells, which have attenuated TGF-b signaling
(Fahlen et al., 2005). These results suggested that
Treg-cell-mediated protection is dependent on the TGF-
b pathway. To determine the function of TGF-b1 that
originated from naive T cells, we also isolated
CD4+Foxp3CD62LhiCD45Rbhi naive T cells from 4cre-
f/n mice or control (wild-type, WT) mice by FACS sorting.
Purified T cells were transferred alone or in combination
into Rag1/ recipients. These mice were monitored for
body-weight change and the development of colitis.
Immunity
In Vivo Function of T Cell-Produced TGF-b1Figure 4. T Cell Activation and Effector
T Cell Differentiation in the Absence of
T Cell-Produced TGF-b1
(A) CD4+ and CD8+ T cells from the mesenteric
lymph nodes of 5-month-old 4cre-f/+ and +/n
mice were analyzed for the expression of
CD44 and CD62L by flow cytometry. Eight
mice per group were analyzed. Representative
results are presented.
(B) Mesenteric-lymph-node CD4+ and CD8+ T
cells of 4cre-f/n and +/n mice at the age of
5 months were analyzed for the expression
of CD122. These are representative results of
five mice per group analyzed.
(C) Mesenteric-lymph-node cells of 4cre-f/n
or littermate control +/n, 4cre-f/+, f/n, or f/f
(WT-Het) mice (n = 8) at 4–7 months old were
stimulated with CD3 and CD28 antibodies for
24 hr. Cytokine amounts in the supernatants
were determined by ELISA. The p values of cy-
tokine amounts between the two groups of
mice are indicated.
(D) Mesenteric-lymph-node CD4+ and CD8+
T cells from 5-month-old 4cre-f/n and +/n
mice were stimulated with PMA and ionomycin
for 4 hr andwere analyzed for the expression of
IL-4, IFN-g, and IL-17. These are representa-
tive results of eight mice per group analyzed.Recipients of WT or 4cre-f/n Treg cells alone gained body
weight (Figure 5A, upper panel) and remained disease free
for up to 12weeks (data not shown). In contrast, transfer of
WT or 4cre-f/n naive T cells resulted in severe body-
weight loss (Figure 5A,middle panel) and the development
of colitis in all recipients in 5 weeks (data not shown).
These observations suggest that TGF-b1 originated from
naive T cells does not play a major role in limiting the
development of colitis.
We also performed cotransfer experiments with Treg
cells and naive T cells in four groups (Figure 5A, lower
panel). Recipients of WT Treg cells and WT naive T cells
gained weight and showed no signs of disease in 8 weeks
(Figures 5A and 5B). Transfer of 4cre-f/n Treg cells andWT
naive T cells resulted in wasting disease and the develop-
ment of colitis in four out of five mice (Figures 5A and 5B),
thus demonstrating an essential role for Treg-cell-pro-
duced TGF-b1 in inhibiting colitis. Rag1/ recipients of
WT Treg cells and 4cre-f/n naive T cells gained weight
and remained disease free (Figures 5A and 5B). However,transfer of 4cre-f/n Treg cells and 4cre-f/n naive T cells led
to the most severe wasting disease and colitis in all recip-
ients (Figures 5A and 5B), suggesting that TGF-b1 origi-
nating from naive T cells also contributed to the protection
of colitis under these conditions. These observations re-
veal an essential role for TGF-b1 produced by Treg cells
and to a lesser extent by nonregulatory T cells in inhibiting
the wasting disease and colitis.
Previous studies showed that colitis that developed in
the transfer model is dependent on Th1 cells and can be
prevented by an antibody that neutralizes IFN-g (Powrie
et al., 1994). To determine the molecular mechanisms by
which Treg-cell-produced TGF-b1 inhibits naive T cell-in-
duced colitis, we FACS sorted naive CD4+ T cells from
C57BL/6 mice that express the congenic marker CD45.1.
Naive T cells were labeled with CFSE andwere transferred
alone or in combination with WT or 4cre-f/n Treg cells that
express the congenic marker CD45.2. The use of different
CD45 markers enabled us to analyze the naive T cell pop-
ulation in recipients. Cotransfer of WT Treg cells did notImmunity 26, 579–591, May 2007 ª2007 Elsevier Inc. 585
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In Vivo Function of T Cell-Produced TGF-b1Figure 5. Failed Inhibition of Colitis and Th1-Cell Differentiation in the Absence of Treg-Cell-Produced TGF-b1
(A) Purified 4cre-f/n or control (wild-type,WT) Treg cells and naive CD4+ T cells were transferred alone or in combination intoRag1/mice. The body-
weight change of these mice is plotted as mean ± SEM.
(B) Treg cells and naive CD4+ T cells from WT and 4cre-f/n mice were transferred to Rag1/ mice in four groups. Representative colon histology is
shown (n = 5).
(C and D) CFSE-labeled CD45.1+ naive T cells were transferred alone or in combination with CD45.2+WT or 4cre-f/n Treg cells intoRag1/mice. One
week later, CD4+ T cells from the mesenteric lymph nodes were stimulated with PMA and ionomycin for 4 hr and were analyzed for IFN-g expression
and CFSE levels. The percentiles of CD45.1+CD4+ T cells that produced IFN-g are depicted in (D). Cotransfer of WT Treg cells but not 4cre-f/n Treg
cells significantly inhibited IFN-g production (p = 0.01).inhibit the proliferation of naive T cells revealed by CFSE
dilution (Figure 5C). However, the frequencies of IFN-g-
producing T cells were markedly reduced in the presence
of WT Treg cells (Figures 5C and 5D). Importantly, inhibi-
tion of IFN-g production was not observed when naive T
cells were transferred with 4cre-f/n Treg cells (Figures
5C and 5D). These observations are consistent with en-
hanced Th1-cell differentiation in 4cre-f/n mice (Figures586 Immunity 26, 579–591, May 2007 ª2007 Elsevier Inc.4C and 4D) and also demonstrate an essential role for
Treg-cell-produced TGF-b1 in inhibiting Th1-cell differen-
tiation in vivo.
T Cell-Produced TGF-b1 Regulation of Th17-Cell
Differentiation and EAE
TGF-b1 is a pleiotropic cytokine with a pivotal role in reg-
ulating the differentiation of effector T cells including the
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Th17-Cell Differentiation in the Absence
of T Cell-Produced TGF-b1
(A) EAE disease course in 4cre-f/n and +/n, f/n,
or 4cre-f/+ (Het) mice (n = 8). Disease scores
are plotted as mean ± SEM. These are repre-
sentative results of two independent experi-
ments.
(B and C) Cytokine production by CD4+ T cells
isolated form the spinal cords day 24 after dis-
ease induction. The cells were stimulated with
PMA and ionomycin for 4 hr and were analyzed
for IFN-g and IL-17 expression. Six out of eight
4cre-f/n mice did not develop any clinical sign
of disease (score 0), whereas the remaining
two developed mild disease (score 2). The rep-
resentative profiles of cytokine staining are
shown in (B). The percentiles of IL-17 and
IFN-g producers in all mice are shown in (C).
The p values of percentiles of cells producing
cytokines between the two groups of mice
are indicated.recently described Th17 cells that secrete the inflamma-
tory cytokine IL-17. Recent studies showed that in the
presence of IL-6, TGF-b promotes the differentiation of
Th17 cells (Bettelli et al., 2006; Veldhoen et al., 2006a). Im-
portantly, Th17 cells are reduced in TGF-b1 complete
knockout mice (Mangan et al., 2006), and CD4-DNR
mice with attenuated TGF-b signaling in T cells fail to de-
velop Th17 cells or EAE (Veldhoen et al., 2006b). These
observations suggest that the TGF-b pathway is important
for the differentiation of Th17 cells in vivo.
Intriguingly, T cell production of IL-17 was greatly re-
duced in 4cre-f/n mice (Figure 4C, 4D), suggesting that
T cell-produced TGF-b1 promoted Th17-cell differentia-
tion. We wished to extend these observations in the EAE
model. 4cre-f/n mice were highly resistant to the induction
of EAE (Figure 6A). Six out of eight 4cre-f/n mice did not
develop disease, and two of them developed mild disease
in contrast to the severe disease developed in all control
mice (Figure 6A). To investigate the function of T cell-pro-
duced TGF-b1 in the regulation of effector T cell differen-
tiation, we assessed the production of IFN-g and IL-17 in
CD4+ T cells that had infiltrated spinal cords. As expected,
populations of CD4+ T cells producing IFN-g or IL-17 were
observed in control n/+ mice (Figures 6B and 6C). How-
ever, the number of IL-17-producing T cells was greatly
reduced in 4cre-f/n mice (Figures 6B and 6C), whereas
IFN-g-positive T cells were not significantly different be-
tween the two groups (Figure 6C). Interestingly, in the
two 4cre-f/n mice that developed mild EAE, infiltrating
CD4+ T cells still produced minimal amounts of IL-17 butgreat amounts of IFN-g (Figures 6B and 6C). These obser-
vations demonstrate an essential role for T cell-produced
TGF-b1 in the differentiation of Th17 cells in the EAE
model.
DISCUSSION
TGF-b1 is a regulatory cytokine with pleiotropic roles in T
cell development, tolerance, and homeostasis (Li et al.,
2006a; Marie et al., 2006). Here, we reported a mouse
model in which the first exon of the Tgfb1 gene and the
fourth exon of the hypothetical gene LOC232987 are
flanked with loxP sites. By breeding these mice to CD4-
Cre transgenic mice, we specifically deleted the loxP-
encompassed genomic region in T cells. Deletion of
Tgfb1 exon 1 inactivated the Tgfb1 gene. The potential
effect of removal of LOC232987 exon 4 was controlled
for by the introduction of a Tgfb1 null allele that has an
intact LOC232987 gene. Therefore, T cells from 4cre-f/n
mice are heterozygous for the exon 4 of LOC232987
gene. 4cre-f/n mice but none of the control mice devel-
oped an inflammatory disorder. With this model, we fur-
ther showed that T cell-produced TGF-b1 inhibited the
expansion of thymic Treg cells and the proliferation, acti-
vation, and differentiation of T cells in peripheral lymphoid
organs. T cell-produced TGF-b1 was dispensable for the
maintenance of peripheral Treg cells but was required
for Treg-cell-mediated suppression of Th1-cell differentia-
tion and colitis in a transfer model. T cells were also vital
sources of TGF-b1 that promoted Th17-cell differentiationImmunity 26, 579–591, May 2007 ª2007 Elsevier Inc. 587
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tant functions for T cell-produced TGF-b1 in the regulation
of T cell tolerance and effector T cell differentiation in vivo.
We have recently reported that TGF-b signaling in T
cells promotes thymic CD8+ T cell maturation and inhibits
thymic Treg cell expansion (Li et al., 2006a). Here, we
show that T cell-produced TGF-b1 is required for the inhi-
bition of Treg cells but is dispensable for CD8+ T cell de-
velopment. These observations suggested that TGF-b1
produced by cells other than T cells is involved in CD8+
T cell maturation or that other isoforms of TGF-b (TGF-
b2 and TGF-b3) are important. Previous studies showed
that thymic epithelial cells produce TGF-b1 (Takahama
et al., 1994). The functions of TGF-b1 produced by these
cells in T cell development are under investigation.
We and others found that TGF-b signaling maintains pe-
ripheral Tregcells and inhibits T cell activation anddifferen-
tiation (Li et al., 2006a; Marie et al., 2006). In this report, we
showed that T cell-produced TGF-b1 suppresses T cell
proliferation, activation, and differentiation but is dispens-
able for the maintenance of peripheral Treg cells. In con-
trast, Treg cells expanded in the absence of T cell-pro-
duced TGF-b1. Increased Treg-cell proliferation was also
observed in T cell-specific TGFbRII-deficient mice, al-
though the cell number was reduced (Li et al., 2006a).
These findings suggested that Treg-cell maintenance is
likely to dependonother cellular sources of TGF-b1. Tode-
termine the status of Treg cells in inflamed tissues, we
compared colonic Treg cells to mesenteric-lymph-node
Treg cells of 4cre-f/n mice. Interestingly, we observed re-
duced Foxp3 levels in colonic Treg cells. We do not know
whether this is a consequenceof the inflammatory environ-
ment in thecolonor is an intrinsicdeficiencydue to lackof T
cell-produced TGF-b1. It is however noteworthy that we
observed reduced Foxp3 levels in Treg cells from the islets
of type I diabetic NOD mice (Wan and Flavell, 2007).
Although T cell-produced TGF-b1 was dispensable for
the maintenance of Treg cells, Treg-cell-produced TGF-
b1 was essential for Treg cell function in vivo. We found
that TGF-b1-deficient Treg cells were defective in inhibit-
ing colitis induced by transferred naive T cells, and this de-
fect was associated with the failure to inhibit naive T cell
differentiation into Th1 cells. Previous studies with Treg
cells isolated from TGF-b1-deficient mice have generated
contrasting results (Fahlen et al., 2005; Kullberg et al.,
2005; Nakamura et al., 2004). The different findings on
the function of Treg-cell-produced TGF-b1 in colitis might
be explained by different gut flora present in different insti-
tutions. In addition, one complication of the earlier studies
is that CD25 was used as a marker for Treg cells, and ac-
tivated T cells may contaminate the Treg-cell population.
This variable was controlled for in our study, because we
isolated Treg cells on the basis of the expression of Foxp3.
A previous study from our laboratory showed that TGF-
b signaling in CD8+ T cells is required for Treg-cell-medi-
ated protection of diabetes (Green et al., 2003). Blockade
of TGF-b signaling in CD8+ T cells also alleviated the inhi-
bition of tumor immunity or cytotoxic T cell function by
Treg cells (Chen et al., 2005; Mempel et al., 2006). These588 Immunity 26, 579–591, May 2007 ª2007 Elsevier Inc.studies reveal that TGF-b1 is also essential for Treg-cell-
mediated inhibition of CD8+ T cell activity. The functions
of Treg-cell-produced TGF-b1 in these disease models
are under investigation.
Nonetheless, TGF-b1-deficient Treg cells possess nor-
mal suppressive activity in vitro. In addition, mice devoid
of Treg cells developed a more severe phenotype than
did 4cre-f/n mice (Fontenot et al., 2003). These observa-
tions suggested that secretionof TGF-b1 is only onemech-
anism of Treg-cell-mediated immune tolerance. Treg cells
may secrete other suppressive cytokines such as IL-10.
The interaction between CTLA-4 on Treg cells and CD80/
CD86 on effector T cells can induce ‘‘outside-in’’ signaling
by CD80 and CD86 ligands and result in suppression
(Paust et al., 2004; Taylor et al., 2004). The functions of
these pathways in vivo remain to be fully established.
Results presented in this study demonstrate an essen-
tial role for T cell-produced TGF-b1 in T cell tolerance.
Although we currently do not know the nature of the acti-
vating stimuli that drive the activation of T cells in 4cre-f/n
mice, the prevalent development of colitis suggests that T
cell responses are directed against commensal bacterium
antigens. Colitis in these mice was associated with en-
hanced Th1 and Th2, but diminished Th17-cell differentia-
tion. It is interesting to note that colitis that developed in
IL-10-deficient mice is dependent on the innate cytokine
IL-23, which promotes Th17-cell differentiation (Yen
et al., 2006). Recent studies have also revealed a pivotal
role for IL-23 in several models of intestinal inflammation,
including Helicobacter hepaticus-triggered T cell-depen-
dent colitis (Kullberg et al., 2006), naive T cell-induced
colitis upon transfer to Rag1/ mice (Hue et al., 2006),
and mucosal inflammation mediated by innate immune
cells (Hue et al., 2006; Uhlig et al., 2006). Interestingly,
these studies show that IL-23 can additionally promote
IL-17 production by innate immune cells (Hue et al.,
2006; Uhlig et al., 2006) and is required for T cell produc-
tion of IFN-g in the transfer model (Hue et al., 2006; Kull-
berg et al., 2006). Importantly, IFN-g precipitates naive T
cell-induced colitis (Powrie et al., 1994) and the colitis trig-
gered by Helicobacter hepaticus infection (Kullberg et al.,
2006). On the basis of these observations, it has been
proposed that IL-23 induces the production of both
IFN-g and IL-17 that synergistically induce intestinal in-
flammation (Kullberg et al., 2006). Because we observed
reduced Th17 cells in 4cre-f/n mice, colitis that developed
in thesemicemay be independent of Th17 cells. Nonethe-
less, it is possible that IL-17 produced by Th17 cells that
remained in 4cre-f/n mice or by other cell types contrib-
utes to the disease pathology. The definitive functions of
IFN-g, IL-17, and Th2 cytokines in colitis that developed
in 4cre-f/n mice remain topics for future investigation. A
recent study showed that colitis developed in IL-10- or
IL-2-deficient mice is differentially regulated by Toll-like
receptor pathways (Rakoff-Nahoum et al., 2006). The
function of Toll-like receptors in colitis developed in
4cre-f/n mice remains to be determined.
An important observation made in this study is that T
cell-produced TGF-b1 is essential for the differentiation
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EAE. This is in contrast to the spontaneous colitis pheno-
type that developed in these mice. These observations
suggest that colitis and EAE can be triggered by different
effector mechanisms. These results are in line with the re-
cent findings that TGF-b promotes Th17-cell differentia-
tion (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen
et al., 2006a) and with the observations that inhibition of
TGF-b signaling in T cells prevents EAE (Veldhoen et al.,
2006b), whereas overexpression of TGF-b1 in T cells ex-
aggerates the disease (Bettelli et al., 2006). We do not
know whether TGF-b1 produced by Treg cells, non-Treg
cells, or both are important for Th17-cell differentiation. In-
terestingly, Treg cells promote Th17-cell differentiation in
the presence of LPS in vitro (Bettelli et al., 2006; Veldhoen
et al., 2006a). A recent study showed that cotransfer of
Treg cells enhances IL-17 but inhibits IFN-g production
(Lohr et al., 2006). These observations suggest a proin-
flammatory role for Treg cells in Th17-cell differentiation
through the production of TGF-b1.
In conclusion, in this report we have uncovered a regula-
tory circuit whereby T cell-produced TGF-b1 essentially
controls T cell tolerance. The finding of a dual role for T
cell TGF-b1 in inhibiting Th1 and promoting Th17-cell dif-
ferentiation can also be exploited for the immunotherapy
of diseases mediated by these effector T cells.
EXPERIMENTAL PROCEDURES
Mice
Mouse genomic DNA of the Tgfb1 gene was isolated from a 129SV
BAC library (Genome Systems). We constructed the targeting vector
by cloning three genomic fragments into plasmid pEasy-Flox. Linear-
ized targeting vector was transfected into ES cells (TC1). Homologous
recombinants were identified by Southern-blot analysis and were
transfected with a pPGK-Cre plasmid for deletion of neomycin selec-
tion marker in vitro. Clones carrying the mutated allele of the Tgfb1
gene TGF-b1f (f) were injected into blastocysts and were implanted
into foster mothers. Chimeric mice were bred to C57BL/6 mice, and
the F1 generation was screened for germline transmission of the mu-
tated allele. GFP knockin mice were similarly generated (M.O.L. and
R.A.F., unpublished data). All mice were backcrossed to C57BL/6
background for eight to nine generations and were maintained under
specific pathogen-free conditions. CD4-Cre transgenic mice and
Foxp3-RFP knockin mice were described previously (Lee et al.,
2001; Wan and Flavell, 2005). All animal experimentation was con-
ducted in accordance with institutional guidelines.
PCR Typing and RT-PCR Analysis
For detection of the wild-type, floxed, and deleted alleles, DNA iso-
lated from different cell types was analyzed by PCR with the following
primer set: 50-CTTCCTAACCCCAGAGGTGGA-30, 50-CACATTAAGTC
GTGGCTAGGG-30, and 50-CCCAGGCTAGCCTTGAACTTCT-30. For
the analysis of LOC232987 expression, RNA was purified from FACS
sorted CD4+ cells with RNeasy Mini Kit (Qiagen), and were reverse
transcribed into cDNA with proSTAR First-Strand RT-PCR Kit (Strata-
gene). cDNA was amplified with the following primer set: 50-CCTGCA
CTTCGCTACTAAAGG-30, and 50-CTAGGCACATGGCAAAAGCCA-30.
Histopathology and Immunohistochemistry
Tissues from sacrificed animals were fixed in Streck Tissue Fixative
(Streck Laboratories) and embedded in paraffin. Five micrometer sec-
tionswere stainedwith hematoxylin and eosin. For detection of IgG de-
position in kidney glomeruli, kidneys were frozen in OCT media, andeight micrometer cryostat sections were cut and fixed in acetone for
10 min. Kidney sections were stained with Alexa-Fluor-488-labeled
goat anti-mouse IgG antibody (Molecular Probes).
ELISA
Cytokine amounts in tissue-culture supernatants were assayed with
ELISA antibody pairs for IL-4, IFN-g (BD Biosciences PharMingen),
and IL-17 (SouthernBiotech) in accordance with the manufacturer’s
recommendations. For detecting TGF-b1, latent TGF-b1 in the culture
supernatant was activated by acid treatment and was assayed with
antibody pairs from R&D Systems (BAF240 and MAB1835). The
amounts of dsDNA antibody and nuclear antibody in mouse sera were
determined with ELISA kits from Alpha Diagnostic International. Sera
from eight 4cre-f/n and eight control f/f, +/n, f/n, or 4cre-f/+ mice
aged 4–7 months were assayed individually with 1:100 dilution of
sera in 1% BSA in PBS.
FACS
Cells from the spleen, lymph nodes, or thymus were depleted of eryth-
rocytes by hypotonic lysis. Cells were preincubated with 2.4G2mAb to
block FcgR for 15 min, and this was followed by the incubation with
specific antibodies for 30 min on ice. All samples were analyzed with
FACSCalibur or LSRII (Becton Dickinson) machines. FACS data were
analyzed with FloJo (Tree Star) software. All antibodies except
Foxp3 and BrdU antibodies were obtained from BD Biosciences Phar-
Mingen. For intracellular cytokine staining, single-cell suspensions
were stimulated with 50 ng/ml PMA (Sigma) and 1 mM ionomycin
(Sigma) for 4 hr; GolgiStop (BD Biosciences PharMingen) was added
for the final 2 hr of culture. After stimulation, cells were first stained
with CD4, CD8, CD45.1, and CD45.2 antibodies, fixed and permeabi-
lized with a Cytofix/Cytoperm kit (BD Biosciences PharMingen), and fi-
nally stained with IFN-g, IL-4, and IL-17 antibodies in accordance with
the manufacturer’s instructions.
BrdU Labeling
Eight-week-old 4cre-f/n or littermate control mice were given
50mg/kg BrdU by i.p. injection. Thymic, splenic, and lymph-node cells
were prepared and stained for cell surface markers and Foxp3
(eBioscience) 16 hr later. Cells were incubated overnight in 1% PFA
and 0.01% Tween 20, and this incubation was followed by Dnase I
(250 u/ml, Sigma) treatment and staining with BrdU antibody (Beckton
Dickinson).
Cell Purification and Culture
CD4+ T cells were enriched from spleen and lymph-node cells by pos-
itive selection with anti-CD4 microbeads (Miltenyi Biotec). Enriched T
cells were further purified with a cell sorter (Becton Dickinson) by gat-
ing on CD4+Foxp3+ (Treg) and CD4+Foxp3-CD62LhiCD45Rbhi (naive)
cells. Spleen cells were also used to purify CD4+TCR-b+ (CD4+ T cells),
CD8+TCR-b+ (CD8+ T cells), B220+ (B cells), and CD11c+ (dendritic
cells) by FACS sorting. The purity of these cells was >95%.We derived
bone-marrow macrophages by growing bone-marrow precursor cells
with L929-cell conditional medium.
For Treg-cell suppression assays, 5 3 104 naive CD4+ T cells were
cultured in 96-well plates with 105 irradiated splenocytes, 2 mg/ml
CD3 antibody, and indicated numbers of Treg cells for 72 hr. Prolifer-
ation of T cells was determined by thymidine incorporation for the final
12–16 hr of the culture. For cytokine-production measurements, 2 3
106 spleen cells were stimulated with 0.1 mg/ml CD3 and 0.5 mg/ml
CD28 antibodies in 2 ml complete medium in 24-well plates. After
24 hr, supernatants were collected and assayed for cytokine amounts
by ELISA. For detecting TGF-b1 production, total CD4+ T cells were
cultured in plates coated with CD3 (5 mg/ml) and CD28 (2 mg/ml) anti-
bodies for 3 days in complete medium supplemented with IL-2
(100 u/ml, BD Biosciences Pharmingen) and were restimulated in
plates coated with CD3 (10 mg/ml) antibody for 24 hr in X-vivo medium
supplemented with Nutridoma-SP (Roche). Sorted CD4+Foxp3+ or
CD4+Foxp3 T cells were also cultured in plates coated with CD3Immunity 26, 579–591, May 2007 ª2007 Elsevier Inc. 589
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supplemented with Nutridoma-SP and IL-2 (106 u/ml).
T Cell Transfer Model of Colitis
A total of 43 105 naive T cells and 13 105 Treg cells were transferred
alone or in combination to Rag1/ mice as described previously
(Powrie et al., 1996). After T cell reconstitution, mice were weighted
weekly and monitored for signs of disease. Naive T cells were also pu-
rified from CD45.1+ C57BL/6 congenic mice, labeled with CFSE, and
transferred alone or in combination with CD45.2+ Treg cells to
Rag1/ mice.
EAE Induction and Disease Scoring
Mice were immunized subcutaneously with 50 mg/mouse MOG 35-55
peptide in 200 ml emulsion of CFA (IFA supplemented with 2.5 mg/ml
Mycobacterium tuberculosis) and were injected on days 0 and 2 with
200 ng/mouse pertussis toxin (List Biological Laboratories). The scor-
ing system used was as follows: 1, limp tail; 2, partial hind-limb paral-
ysis; 3, total hind-limb paralysis; 4, hind-limb paralysis and 75% body
paralysis; and 5, complete body paralysis/moribund.
Isolation of Mononuclear Cells from Spinal Cords
Mononuclear cells from spinal cords were isolated as described previ-
ously (Ivanov et al., 2006). In brief, mice were perfused with 30 ml PBS
with 2 mM EDTA. Spinal cords were dissected, cut into pieces, and di-
gested in PBS supplemented with 10 mg/ml Collagenase D (Roche).
The digested spinal cords were vortexed intensively and passed
through a 40 mm cell strainer. Cells were washed in PBS, resuspended
in 6ml 38% Percoll solution (GE Healthcare), and pelleted for 20min at
2000 rpm. Cells were washed in PBS and used in experiments.
Statistical Analyses
The Student’s t test was used to calculate statistical significance for
difference in a particular measurement between groups. A p value of
%0.05 was considered statistically significant.
Supplemental Data
Four figures are available online at http://www.immunity.com/cgi/
content/full/26/5/579/DC1/.
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